U.S. Entertainment Stock News

NYSE:EL
NYSE:ELPersonal Products

Is Estée Lauder (EL) Finally Turning A Corner After Recent Share Price Rebound

If you are wondering whether Estée Lauder Companies at around US$82.85 is giving you fair value, a discount, or an expensive ticket to future expectations, this breakdown is for you. The stock has returned 7.5% over the last week and 19.9% over the last month, while the 1 year return is 43.8%. However, the 3 year and 5 year returns are 56.5% and 69.8% declines, which raises real questions about how to read the current price. Recent coverage has focused on how the share price has moved...
NYSE:APLE
NYSE:APLEHotel and Resort REITs

Apple Hospitality REIT (APLE) Q1 FFO Stability Tests Bearish Margin Narratives

Apple Hospitality REIT’s Q1 2026 Earnings Snapshot Apple Hospitality REIT (APLE) opened 2026 with Q1 Funds From Operations of US$76.5 million and trailing 12 month net profit margins of 12.4%, while the stock trades around US$13.61. Over the past reported quarters, revenue has moved from US$333.0 million in Q4 2024 to US$327.7 million in Q1 2025 and US$326.4 million in Q4 2025, alongside basic EPS readings between US$0.12 and US$0.27 and trailing 12 month FFO in the US$359.2 million range...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

Did Higher 2026 Guidance and XOMA Deal Just Shift Ligand Pharmaceuticals' (LGND) Investment Narrative?

Ligand Pharmaceuticals recently raised its 2026 revenue guidance to a range of US$270 million to US$310 million and discussed its planned acquisition of XOMA Royalty, while also participating in several investor conferences, including the H.C. Wainwright Royalty Company Virtual Conference on May 6, 2026. This combination of higher guidance, an expanded royalty portfolio through the proposed XOMA Royalty acquisition, and active investor outreach could reshape how investors view Ligand’s...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Approval And Rusfertide Priority Review

Why Protagonist Therapeutics Stock Is Back in Focus Protagonist Therapeutics (PTGX) is in the spotlight after FDA approval of ICOTYDE for moderate to severe plaque psoriasis, a Priority Review for rusfertide, and a Takeda opt out that triggers substantial payments. See our latest analysis for Protagonist Therapeutics. Despite the recent pullback, with a 1-month share price return of 4.4% and a 7-day share price return of 2%, Protagonist Therapeutics still has a 90-day share price return of...
NYSE:PGR
NYSE:PGRInsurance

Progressive Expands UpPayment Program As Investors Weigh Homeowners Growth Potential

Progressive (NYSE:PGR) is expanding its UpPayment program to offer larger down payment assistance for first-time homebuyers. The initiative aims to support hundreds of eligible applicants as part of a broader push to make homeownership more accessible. The program expansion is positioned within Progressive's wider homeownership and community engagement efforts. Progressive, trading at around $197.74, is drawing attention not for its share price moves but for this new push into direct...
NYSE:UVE
NYSE:UVEInsurance

A Look At Universal Insurance Holdings (UVE) Valuation After Recent Share Price Strength

Initial market context for Universal Insurance Holdings (UVE) Universal Insurance Holdings (UVE) has drawn investor attention after recent share price moves, with the stock last closing at $39.77 and showing mixed short term performance alongside stronger one month and past three month returns. See our latest analysis for Universal Insurance Holdings. At a share price of $39.77, UVE’s recent 1 day gain and 7 day pullback sit against a stronger 30 day share price return of 19.43% and a 1 year...
NYSE:ITW
NYSE:ITWMachinery

Why Illinois Tool Works (ITW) Is Down 5.2% After Raising 2026 EPS Guidance And Completing Buybacks

In the first quarter of 2026, Illinois Tool Works Inc. reported sales of US$4,016 million and net income of US$768 million, with diluted earnings per share from continuing operations rising to US$2.66 from US$2.38 a year earlier. Alongside these results, the company lifted its 2026 GAAP EPS guidance, targeted higher operating margins backed by enterprise initiatives, and completed a multi‑year US$3.38 billion share repurchase program that reduced its share count by 4.54%. We’ll now examine...
NasdaqCM:SATL
NasdaqCM:SATLAerospace & Defense

Satellogic Hires Industry Veterans As Sovereign Geo-Intelligence Strategy Meets Market Hype

Satellogic (NasdaqCM:SATL) has expanded its global sales organization with three senior industry veterans focused on sovereign geospatial intelligence customers. The hires are aimed at deepening relationships with defense and intelligence agencies and supporting the company's wider commercial push. For investors tracking NasdaqCM:SATL, these leadership additions come after the previously announced $12 million satellite transfer agreement and at a time when the stock is trading around $7.0...
NYSE:VICI
NYSE:VICISpecialized REITs

VICI Expands Casino And Experiential Portfolio While Shares Screen Undervalued

VICI Properties (NYSE:VICI) completed a $1.2b sale leaseback acquisition of seven casinos from Golden Entertainment. The deal adds multiple Las Vegas area properties to VICI’s portfolio, expanding its role as a landlord in gaming real estate. Golden used transaction proceeds to address existing debt, while VICI secured new long term rental income streams. Alongside this transaction, VICI has announced new investments and an expansion into alternative experiential assets. For investors...
NasdaqGS:TEAM
NasdaqGS:TEAMSoftware

Is It Time To Revisit Atlassian (TEAM) After Recent 32% Weekly Price Surge?

Wondering whether Atlassian at around US$92.35 is priced attractively or still looks expensive? This article breaks down what that current market price might imply about the stock's value. The share price has moved sharply in the short term, with a 32.5% return over the last 7 days and 35.2% over the last 30 days, while longer term returns sit at a 40.3% decline year to date and a 55.6% decline over the last year. Recent coverage has focused on Atlassian as a key software platform provider,...
NYSE:RACE
NYSE:RACEAuto

Is Ferrari (NYSE:RACE) Now A Luxury Bargain After A 30% Share Price Slide?

Wondering if Ferrari stock at around US$325 is a premium worth paying or a potential bargain hiding in plain sight? This article walks through the key numbers so you can judge the value for yourself. The stock is down about 5% over the last 7 days, 4.3% over the last month, 12.5% year to date and 30.6% over the past year. Over a longer horizon, the 3 year and 5 year returns sit at 13.5% and 71.1% respectively. Recent coverage has focused on Ferrari as a high end auto stock, with attention on...
NasdaqGS:HSIC
NasdaqGS:HSICHealthcare

Henry Schein (HSIC) Margins Hold Near 3% And Keep Profitability Debate Alive Heading Into Q1

Henry Schein (HSIC) sets the stage with steady top line and consistent earnings Henry Schein (HSIC) opened Q1 2026 earnings season on the back of Q4 2025 revenue of about $3.4 billion and basic EPS of $0.86, with trailing twelve month figures at $13.2 billion of revenue and EPS of $3.29 helping frame the latest print. Over the past year, revenue has moved from $12.7 billion to $13.2 billion while trailing EPS shifted from $3.08 to $3.29, giving you a clearer sense of how the top line and per...
NasdaqGS:YORW
NasdaqGS:YORWWater Utilities

York Water (YORW) Margin Slippage Tests Premium P/E Growth Narrative

York Water’s latest earnings snapshot York Water (YORW) has just posted another quarter of steady utility earnings, with Q4 2025 revenue at US$19.5 million and basic EPS of US$0.36, supported by trailing 12 month revenue of US$77.5 million and EPS of US$1.39. Over recent quarters the company has seen revenue range between US$18.5 million and US$20.4 million, with quarterly EPS between US$0.25 and US$0.43. The trailing net profit margin sits at 25.9% compared with 27.1% a year earlier, which...
NYSE:XOM
NYSE:XOMOil and Gas

Exxon Mobil (XOM) Margin Decline Puts Premium P/E And Bullish Narratives Under Scrutiny

Exxon Mobil (XOM) opened 2026 with first quarter revenue of US$83.2b, basic EPS of US$1.00, and net income of US$4.2b, setting the tone for how the market will judge its latest move in profitability. Over the past year, revenue on a trailing basis has held around US$326.0b while trailing EPS has been about US$5.94, giving investors a clearer sense of how the current quarter fits into the recent earnings run rate. With the stock trading at US$154.88 and trailing net margin at 7.8% versus 9.8%...
NasdaqGS:PLMR
NasdaqGS:PLMRInsurance

Is Palomar Holdings (PLMR) Attractive After Recent Share Price Pullback?

Wondering whether Palomar Holdings at around US$111.73 is priced for opportunity or risk? This article breaks the stock down so you can judge the value for yourself. The share price has seen a 12.1% pullback over the last 7 days and is down 15.2% year to date, after a 28.5% decline over the past year and a 128.2% gain across the last 3 years. Recent headlines around Palomar have focused on its position within the insurance sector and how investors are reassessing risk for specialty insurers...
NYSE:JLL
NYSE:JLLReal Estate

A Look At Jones Lang LaSalle (JLL) Valuation After Strong First Quarter Sales And Net Income Growth

Jones Lang LaSalle (JLL) opened its latest update with a first quarter earnings release showing higher sales and net income than a year earlier, a combination that helped frame the stock’s recent move. See our latest analysis for Jones Lang LaSalle. The strong first quarter update and the recent completion of a sizeable buyback program, which retired 15.66% of shares over several years, come as the stock trades at US$318.13. Despite a 6.86% 7 day share price decline and a 5.27% year to date...
NasdaqGM:STIM
NasdaqGM:STIMMedical Equipment

Neuronetics (STIM) Margin Compression Reinforces Bearish Clinic Mix Narrative

Neuronetics (STIM) has just put fresh numbers on the table for Q1 2026, and recent filings show quarterly revenue at US$41.8 million in Q4 2025 with a basic EPS loss of US$0.10, alongside trailing twelve month revenue of US$149.2 million and a basic EPS loss of US$0.59. Over recent quarters, the company has seen revenue move from US$18.5 million in Q3 2024 to US$22.5 million in Q4 2024 and then to US$42.8 million in Q4 2025, while quarterly basic EPS losses shifted from US$0.44 to US$0.35 and...
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

Does Credo Technology Group Holding (CRDO) Still Offer Value After Its 306% One-Year Surge?

Investors may be wondering whether Credo Technology Group Holding is still attractively priced after its substantial share price increase, or if expectations have already moved too far ahead of the business. The stock last closed at US$193.57, with returns of 16.7% over 7 days, 90.8% over 30 days, 35.2% year to date and 306.1% over the past year, plus a very large 3-year return of 2,453.7%. Recent coverage has focused on Credo as a high growth semiconductor stock, with investors watching...
NYSE:BAX
NYSE:BAXMedical Equipment

Assessing Baxter International’s Valuation After Earnings Beat And Guidance Reaffirmation

Why Baxter International (BAX) is back on investors’ radar Baxter International (BAX) moved back into focus after first quarter results topped revenue and non GAAP profit expectations, management reiterated full year earnings guidance, and analysts responded with more constructive commentary on the stock. See our latest analysis for Baxter International. The better than expected first quarter and reaffirmed full year earnings guidance came after a tough stretch for shareholders, with a 90 day...
NYSE:GPK
NYSE:GPKPackaging

Graphic Packaging Holding (GPK) Margin Compression Tests Bullish Earnings Growth Narrative

Graphic Packaging Holding (GPK) opened 2026 on the back of a steady 2025, with Q4 revenue of US$2.1b, basic EPS of US$0.24 and net income of US$71m, framing expectations for the latest Q1 print. Over recent quarters, the company has seen quarterly revenue move in a narrow band between US$2.1b and US$2.2b, while basic EPS ranged from US$0.24 to US$0.55. This sets up a picture where investors are focusing less on sheer top line scale and more on how much of that flows through to profit. With...
NYSE:DOV
NYSE:DOVMachinery

Dover’s 2026 EPS Guidance and Revenue Outlook Could Be A Game Changer For Dover (DOV)

Dover Corporation recently reported past first-quarter 2026 results, with sales rising to US$2,053.62 million and net income at US$238.43 million, alongside modest increases in both basic and diluted earnings per share. The company also issued full-year 2026 guidance, projecting GAAP EPS between US$8.92 and US$9.12 on expected revenue growth of 5% to 7%, offering fresh insight into its earnings trajectory. We’ll now examine how Dover’s updated 2026 EPS guidance and revenue growth outlook...
NasdaqGS:SNEX
NasdaqGS:SNEXCapital Markets

What StoneX Group (SNEX)'s Q1 2026 Earnings and Insider Equity Moves Mean For Shareholders

StoneX Group Inc. is set to report its Q1 2026 earnings after market close, following a prior quarter that surpassed analysts’ EPS estimates and amid upbeat growth-focused research coverage. At the same time, the company’s board activity shows a mix of insider share sales, new restricted stock grants, and a Form 144 filing, offering a detailed view of how directors are managing and being compensated with equity. With Q1 results due and analysts highlighting earnings growth potential, we’ll...
NasdaqGS:KNSA
NasdaqGS:KNSABiotechs

Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next

In late April 2026, Kiniksa Pharmaceuticals International, plc reported past first-quarter 2026 results, with revenue of US$214.27 million and net income of US$22.59 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. On the same day, the company raised its 2026 net product revenue outlook to a range of US$930 million to US$945 million, signaling greater confidence in its ARCALYST franchise and overall portfolio execution. Now,...